ORCHARD THERAPEUTICS PLC.
History
| Year | Detail |
|---|---|
| 2015 | Orchard Therapeutics plc was established to bring hematopoietic stem cell (HSC) gene therapy to patients with devastating genetic diseases. |
| 2016 | Orchard Therapeutics plc launched with a $33 million Series A financing led by F-Prime Capital. At launch, the company has development programs in adenosine deaminase severe combined immunodeficiency (ADA-SCID) and mucopolysaccharidosis type IIIA (MPS-IIIA). |
| Orchard Therapeutics plc established a new office in Foster City, California, and started its operation in the U.S. | |
| 2018 | Orchard Therapeutics plc was listed on the U.S. Nasdaq stock exchange under the "ORTX." |
| 2024 | Orchard Therapeutics plc was acquired by Kyowa Kirin, one of Japan's leading specialty pharmaceutical companies, for $477.6 million. This acquisition will enhance Kyowa Kirin's operations and address the unmet medical needs of individuals with genetic and other severe diseases. |
BCC Research Beacon 